Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy.
about
Second-line treatment of metastatic gastric cancer: Current options and future directionsOxaliplatin with biweekly low dose leucovorin and bolus and continuous infusion of 5-fluorouracil (modified FOLFOX 4) as a salvage therapy for patients with advanced gastric cancer.Phase II study of sunitinib as second-line treatment for advanced gastric cancer.Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trialsA phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer.Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancerIrinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicitiesSalvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer.Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancerRecent developments in chemotherapy of advanced gastric cancer.A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy.Recent developments in the systemic therapy of advanced gastroesophageal malignancies.A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance statusCapecitabine in the treatment of advanced gastric cancer.A phase II study of paclitaxel and cisplatin as salvage therapy for patients with advanced or metastatic gastric cancer.Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study.Management of advanced gastric cancer.Second-line chemotherapy for advanced gastric cancer in Korea.EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells.Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer.Safety and continuity of second- and third-line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer.Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable diseaseMetastatic gastric cancer treatment: Second line and beyond.A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma.CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group.Efficacy and safety study of docetaxel as salvage chemotherapy in metastatic gastric cancer failing fluoropyrimidine and platinum combination chemotherapy.Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum.
P2860
Q26778027-35B49B84-78AA-49FB-B60B-7B6FF7F17469Q33387297-B85FDB38-7B06-4959-9A25-65ACF0C215E3Q33389519-A36CE2E9-06FE-44CD-8376-815C3209E4A8Q33393276-7752B0F3-5423-446B-AE00-7D2F2099B0CEQ33421868-37B63525-A620-47B0-AC04-CDECC9159793Q33766456-4B9BB5D2-19AD-4880-ACEF-13CB903004F7Q34484362-254E583B-BE26-4960-BD0F-218DE9807F79Q35233550-8C655A48-F1BA-415A-BF96-DE59675CEA31Q35949510-569EC0A2-B7A3-4E1B-A803-0ADB58C32AEDQ36065419-9E1DCC87-F471-4662-BFB3-A3A9A85FED38Q36090047-0E8821C9-018E-444E-BDB1-2F04165718ADQ36275405-3BC53E43-7783-4B65-8264-95AC943147CAQ36376439-91311254-32D6-42EC-9CAE-B2EF8994EE9CQ36610995-38649BDE-91C1-401C-BB61-118747E41969Q37136996-D99AA6A8-E616-414F-955A-F2051E563330Q37336461-FBA46189-105D-4B62-9AC1-79C08D732966Q37425848-7194C9C6-0B02-42EF-A6EC-F9D8CAF38A97Q37989161-E5719C3B-03C9-4CEE-B1DE-F4CE5A47CD66Q37992841-CB40FC47-7259-45F9-A22F-74BA0D2B7380Q38699981-80B6008B-B90F-49DA-867C-7FE85E56DC3EQ38823650-60F8CDC2-3DCF-41AE-B82B-9D22BD0EDE72Q38956887-432F09E7-9AC4-4B8B-B666-4A6AE8F8BCEBQ40888760-4016AC40-9911-44F4-8DCB-9E4B38677BF9Q42957434-B598ED48-E9E7-47B1-95DB-CFAAFC6D2C48Q44923328-70B78859-5F92-408C-8308-B7FF8EA8F216Q46817815-9AE40FCD-BCA4-4F73-8E77-C486A10D9564Q49504289-A019B86C-A1AE-4CCD-9519-DF09520F676CQ49657442-DBB7F9D6-5955-4329-8726-6AAEA0F3C77BQ50285053-E793B5E4-2403-44BF-8A37-4D4CA18C9CA2Q51048811-CF31D72D-18C7-4D9C-B654-42E1391EC93F
P2860
Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Weekly irinotecan in patients ...... cisplatin-based chemotherapy.
@en
type
label
Weekly irinotecan in patients ...... cisplatin-based chemotherapy.
@en
prefLabel
Weekly irinotecan in patients ...... cisplatin-based chemotherapy.
@en
P2093
P356
P1476
Weekly irinotecan in patients ...... cisplatin-based chemotherapy.
@en
P2093
Hark Kyun Kim
Hong Gi Lee
Il Ju Choi
Jae-Moon Bae
Jin Yi Choi
Jong Ho Chun
Jong Seok Lee
Keun Won Ryu
Sung Min Yoon
P356
10.1093/JJCO/HYH006
P577
2004-01-01T00:00:00Z